Skip to Content

Hologic Inc HOLX

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Hologic Rides COVID-19 Testing Wave; Raising Our Fair Value

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Thanks to the pandemic, Hologic delivered an astounding fiscal first quarter that featured organic growth of 104% year over year, driven by molecular diagnostics. We’re modestly raising our fair value estimate after adjusting our expectations for this strength to continue through this calendar year followed by softening in 2022 and 2023 as herd immunity is achieved globally. If the new viral variants from Brazil or South Africa become widespread, or if further obstacles crop up to slow vaccinations, we might adjust our expectations for demand to last into 2022. We give narrow-moat Hologic kudos for increasing its production capacity of the Panther platform machines, as well as the consumable SARS-CoV-2 tests. Seeing this display of operational excellence gives us more confidence that Hologic is well equipped to integrate the various acquisitions it has made of late to beef up its product portfolio.

Read Full Analysis

Company Profile

Business Description

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.

250 Campus Drive
Marlborough, MA, 01752
T +1 508 263-2900
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Dec 31, 2020
Fiscal Year End Sep 26, 2021
Stock Type Classic Growth
Employees 5,814